Article Figures & Data
Figures
- Fig. 1.
Immunization with WI-1 induces delayed-type hypersensitivity responses in a concentration-dependent manner. Groups of three C57BL/6 mice were immunized with various doses of WI-1 or live yeast according to the protocol described in Materials and Methods. Mice were tested 2 weeks after the second immunization for delayed-type hypersensitivity by administration of 10 μg of WI-1 in saline into one footpad and saline alone into the other footpad. Measurements were taken 24 h later. Error bars represent standard errors of the mean.
- Fig. 2.
Anti-WI-1 IgG subclasses in four C57BL/6 mice per group immunized with either 100 μg of WI-1, 106 heat-killed yeasts (HK Yst), or 4 × 104 live yeast (Live Yst) subcutaneously (A) and three C57BL/6 mice per group immunized with various doses of WI-1 as shown (B). In each experiment, sera were obtained 2 weeks after the second immunization and analyzed for anti-WI-1 IgG subclass by ELISA. Error bars indicate standard error of the mean. OD, optical density. NMS, normal mouse serum.
- Fig. 3.
Protective efficacy of WI-1 immunization against lethal pulmonary blastomycosis. Groups of C57BL/6 mice were immunized subcutaneously either with 100 μg of WI-1 or with BSA according to the protocol described in Materials and Methods. Two weeks after a second immunization, the mice were challenged with a lethal dose of 104B. dermatitidis ATCC 60636 yeasts and observed for survival. Kaplan-Meier survival curves were generated for WI-1-immunized mice and control mice during an observation interval of 30 days after experimental infection.
Tables
- Table 1.
WI-1 prolongs the survival of mice challenged with a lethal dose of B. dermatitidisa
Expt Mouse strains Group (n) Mean survival (days) % Survival at 30 days postinfection (no. of mice that survived/total no. of mice) Significanceb (P) 1 C57BL/6 WI-1 (8) 28 75 (6/8) 0.0002 BSA (8) 18 0 2 C57BL/6 WI-1 (11) 21 27 (3/11) 0.0002 BSA (14) 15 0 3 C57BL/6 WI-1, 200 μg (12) 17 0 0.009 WI-1, 10 μg (12) 13 0 4 BALB/c WI-1 (8) 21 25 (2/8) 0.027 BSA (8) 16 0 5 C57BL/6 Histo/WI-1 (7) 25 29 (2/7) 0.026† Histo alone (15) 20 0 0.045‡ Unimmunized (10) 18 10 (1/10) ↵a Summary of five separate protection experiments performed in C57BL/6 mice and BALB/c mice. C57BL/6 or BALB/c mice were immunized with WI-1 or BSA according to the protocol described in Materials and Methods. Mice were observed for survival after intranasal infection with a lethal dose of 104 ATCC 60636 yeasts. In experiment 5, mice were intranasally infected twice (1 month apart) with a sublethal dose of either H. capsulatum184 AS ura 5-11 expressing WI-1 off the telomeric, extrachromosomal plasmid pMAD93/WI-1 (Histo/WI-1) or the control strain transformed with plasmid pMAD93 lacking WI-1 (Histo alone). These immunized and control mice were challenged intranasally with a lethal dose of 104 ATCC 26199 yeasts 2 weeks after the second immunization and monitored for survival.
↵b Two-sided P value. †, comparison of Histo/WI-1 group versus Histo alone group; ‡, comparison of Histo/WI-1 group versus unimmunized group.
